Clinical significance of incidental finding of focal activity in the breast at 18F-FDG PET/CT

American Journal of Roentgenology

Volumn 197, Issue 2, 2011, Pages 341-347

  Kang, Bong Joo ^a   Lee, Ji Hye ^a   Yoo, Ie Ryung ^a   Kim, Sung Hun ^a   Choi, Jae Jeong ^a   Jeong, Seung Hee ^a   Yim, Hyeon Woo ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Breast cancer; CT; FDG PET; Sonography

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; ADVANCED CANCER; ARTICLE; BREAST BIOPSY; BREAST CANCER; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DIGITAL MAMMOGRAPHY; DRUG UPTAKE; ECHOMAMMOGRAPHY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMAGE PROCESSING; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

AGED; BREAST NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; INCIDENTAL FINDINGS; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; TOMOGRAPHY, X-RAY COMPUTED; ULTRASONOGRAPHY, MAMMARY;

EID: 79960722471     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.10.6126     Document Type: Article

References (25)

1. Avril N, Rose CA, Schelling M, et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol 2000; 18:3495-3502
2. Bar-Shalom R, Valdivia AY, Blaufox MD. PET imaging in oncology. Semin Nucl Med 2000; 30:150-185 (Pubitemid 30469914)
3. Bohuslavizki KH, Klutmann S, Kroger S, et al. FDG PET detection of unknown primary tumors. J Nucl Med 2000; 41:816-822 (Pubitemid 30266025)
4. Kostakoglu L, Agress H Jr, Goldsmith SJ. Clinical role of FDG PET in evaluation of cancer patients. RadioGraphics 2003; 23:315-340; quiz, 533
5. Eubank WB, Mankoff DA. Evolving role of positron emission tomography in breast cancer imaging. Semin Nucl Med 2005; 35:84-99 (Pubitemid 40568742)
6. 18F-fluorodeoxyglucose positron emission tomography with the additional help of tumor markers in cancer screening. Neoplasma 2003; 50:217-221
7. Yasuda S, Ide M, Fujii H, et al. Application of positron emission tomography imaging to cancer screening. Br J Cancer 2000; 83:1607-1611 (Pubitemid 32001701)
8. Dong C, Hemminki K. Second primary neoplasms among 53 159 haematolymphoproliferative malignancy patients in Sweden, 1958-1996: a search for common mechanisms. Br J Cancer 2001; 85:997-1005 (Pubitemid 33016003)
9. Ishimori T, Patel PV, Wahl RL. Detection of unexpected additional primary malignancies with PET/CT. J Nucl Med 2005; 46:752-757
10. Ueno M, Muto T, Oya M, Ota H, Azekura K, Yamaguchi T. Multiple primary cancer: an experience at the Cancer Institute Hospital with special reference to colorectal cancer. Int J Clin Oncol 2003; 8:162-167 (Pubitemid 36897286)
11. Litmanovich D, Gourevich K, Israel O, Gallimidi Z. Unexpected foci of (18)F-FDG uptake in the breast detected by PET/CT: incidence and clinical significance. Eur J Nucl Med Mol Imaging 2009; 36:1558-1564
12. D'Orsi CJ, Bassett LW, Berg WA, et al. BI-RADS: mammography, 4th ed. In: D'Orsi CJ, Mendelson EB, Ikeda DM, et al. Breast Imaging Reporting and Data System: ACR BI-RADS - breast imaging atlas. Reston, VA: American College of Radiology, 2003
13. Inoue M, Sano T, Watai R, et al. Dynamic multi-detector CT of breast tumors: diagnostic features and comparison with conventional techniques. AJR 2003; 181:679-686 (Pubitemid 37021835)
14. Korn RL, Yost AM, May C, et al. Unexpected focal hypermetabolic activity in the breast: significance in patients undergoing 18F-FDG PET/CT. AJR 2006; 187:81-85 (Pubitemid 46100149)
15. Yasuda S, Ide M. PET and cancer screening. Ann Nucl Med 2005; 19:167-177 (Pubitemid 40874507)
16. Kolb TM, Lichy J, Newhouse JH. Occult cancer in women with dense breasts: detection with screening US - diagnostic yield and tumor characteristics. Radiology 1998; 207:191-199
17. McDonough MD, DePeri ER, Mincey BA. The role of positron emission tomographic imaging in breast cancer. Curr Oncol Rep 2004; 6:62-68 (Pubitemid 38898832)
18. Avril N, Adler LP. F-18 fluorodeoxyglucose-positron emission tomography imaging for primary breast cancer and loco-regional staging. Radiol Clin North Am 2007; 45:645-657 (Pubitemid 47238389)
19. Buck A, Schirrmeister H, Kühn T, et al. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging 2002; 29:1317-1323 (Pubitemid 44392212)
20. Rosé C, Dose J, Avril N. Positron emission tomography for the diagnosis of breast cancer. Nucl Med Commun 2002; 23:613-618 (Pubitemid 34747999)
21. Schilling K, Narayanan D, Kalinyak JE, et al. Positron emission mammography in breast cancer presurgical planning: comparisons with magnetic resonance imaging. Eur J Nucl Med Mol Imaging 2011; 38:23-36
22. Weinberg IN, Beylin D, Zavarzin V, et al. Positron emission mammography: high-resolution biochemical breast imaging. Technol Cancer Res Treat 2005; 4:55-60 (Pubitemid 40189670)
23. Berg WA, Weinberg IN, Narayanan D, et al. Highresolution fluorodeoxyglucose positron emission tomography with compression ("positron emission mammography") is highly accurate in depicting primary breast cancer. Breast J 2006; 12:309-323 (Pubitemid 43989975)
24. 99mTc-sestamibi and magnetic resonance imaging in the diagnosis of breast cancer: a comparative study. Breast J 2007; 13:465-469
25. Brem RF, Floerke AC, Rapelyea JA, Teal C, Kelly T, Mathur V. Breast-specific gamma imaging as an adjunct imaging modality for the diagnosis of breast cancer. Radiology 2008; 247:651-657